Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
| SRPT Stock | USD 102.86 1.64 1.62% |
Slightly above 51% of Sarepta Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Sarepta Therapeutics suggests that some traders are interested. Sarepta Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Sarepta Therapeutics' earnings reports, geopolitical events, and overall market trends.
Sarepta |
Filed transaction by Sarepta Therapeutics Officer Chief Customer Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Sarepta Therapeutics Fundamental Analysis
We analyze Sarepta Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sarepta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sarepta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Sarepta Therapeutics is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Sarepta Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sarepta Therapeutics stock to make a market-neutral strategy. Peer analysis of Sarepta Therapeutics could also be used in its relative valuation, which is a method of valuing Sarepta Therapeutics by comparing valuation metrics with similar companies.
Peers
Sarepta Therapeutics Related Equities
| VKTX | Viking Therapeutics | 9.30 | ||||
| TERN | Terns Pharmaceuticals | 3.54 | ||||
| MDGL | Madrigal Pharmaceuticals | 2.50 | ||||
| KRYS | Krystal Biotech | 1.97 | ||||
| PTCT | PTC Therapeutics | 2.02 | ||||
| AKRO | Akero Therapeutics | 2.22 | ||||
| IOVA | Iovance Biotherapeutics | 2.97 |
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.